BACKGROUND: This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. METHODS: HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. RESULTS: There was no interaction between etiology and treatment for the primary outcome (P = .73), cardiovascular (CV) mortality or CV hospitalization (P = .59), or CV mortality or HF hospitalization (P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality (P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors (P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. CONCLUSION: Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.
RCT Entities:
BACKGROUND: This post hoc analysis of the HF-ACTION cohort explores the primary and secondary results of the HF-ACTION study by etiology and severity of illness. METHODS: HF-ACTION randomized stable outpatients with reduced left ventricular (LV) function and heart failure (HF) symptoms to either supervised exercise training plus usual care or to usual care alone. The primary outcome was all-cause mortality or all-cause hospitalization; secondary outcomes included all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or HF hospitalization. The interaction between treatment and risk variable, etiology or severity as determined by risk score, New York Heart Association class, and duration of cardiopulmonary exercise test was examined in a Cox proportional hazards model for all clinical end points. RESULTS: There was no interaction between etiology and treatment for the primary outcome (P = .73), cardiovascular (CV) mortality or CV hospitalization (P = .59), or CV mortality or HF hospitalization (P = .07). There was a significant interaction between etiology and treatment for the outcome of mortality (P = .03), but the interaction was no longer significant when adjusted for HF-ACTION adjustment model predictors (P = .08). There was no significant interaction between treatment effect and severity, except a significant interaction between cardiopulmonary exercise duration and training was identified for the primary outcome of all-cause mortality or all-cause hospitalization. CONCLUSION: Consideration of symptomatic (New York Heart Association classes II to IV) patients with HF with reduced LV function for participation in an exercise training program should be made independent of the cause of HF or the severity of the symptoms.
Authors: Rod S Taylor; Allan Brown; Shah Ebrahim; Judith Jolliffe; Hussein Noorani; Karen Rees; Becky Skidmore; James A Stone; David R Thompson; Neil Oldridge Journal: Am J Med Date: 2004-05-15 Impact factor: 4.965
Authors: Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews Journal: N Engl J Med Date: 2002-03-19 Impact factor: 91.245
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Emily P Zeitler; Jonathan P Piccini; Anne S Hellkamp; David J Whellan; Kevin P Jackson; Stephen J Ellis; William E Kraus; Steven J Keteyian; Dalane W Kitzman; Gregory A Ewald; Jerome L Fleg; Ileana L Piña; Christopher M O'Connor Journal: J Card Fail Date: 2014-10-15 Impact factor: 5.712
Authors: Vernon W Dolinsky; Kyle J Rogan; Miranda M Sung; Beshay N Zordoky; Mark J Haykowsky; Martin E Young; Lee W Jones; Jason R B Dyck Journal: Am J Physiol Endocrinol Metab Date: 2013-05-21 Impact factor: 4.310
Authors: Holly R Middlekauff; M Anthony Verity; Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; Perry Shieh Journal: Clin Res Cardiol Date: 2013-04-11 Impact factor: 5.460
Authors: Marino DiFranco; Marbella Quiñonez; Perry Shieh; Gregg C Fonarow; Daniel Cruz; Mario C Deng; Julio L Vergara; Holly R Middlekauff Journal: PLoS One Date: 2014-10-13 Impact factor: 3.240
Authors: Dominika Szalewska; Renata Główczyńska; Ryszard Piotrowicz; Ilona Kowalik; Michael J Pencina; Grzegorz Opolski; Wojciech Zaręba; Maciej Banach; Piotr Orzechowski; Sławomir Pluta; Robert Irzmański; Zbigniew Kalarus; Ewa Piotrowicz Journal: ESC Heart Fail Date: 2021-02-01